PDRN for Lichen Sclerosus: The Regenerative Treatment Most Patients Have Never Heard Of

Most people with lichen sclerosus have been told some version of the same thing: use your steroid, protect the skin, manage triggers, and accept that this is a lifelong condition with no cure. That framework is not wrong. But it is incomplete in one specific and consequential way, and that gap matters enormously for a subset of patients who are doing everything right and still struggling.

Steroids are excellent at controlling the immune inflammation that drives LS. What they do not do is rebuild atrophic tissue, restore vascular supply to depleted epithelium, or support the regenerative processes that fragile LS tissue desperately needs between flares. For many patients, inflammation is reasonably controlled but the tissue itself remains thin, slow to heal, prone to fissuring, and structurally depleted in ways that standard management simply does not address.

This is the biological gap that PDRN, polydeoxyribonucleotide, is designed to fill. It has published clinical data specifically in lichen sclerosus. It has a coherent, well-characterized mechanism. It has an excellent safety profile across multiple tissue types including genital mucosa. And the overwhelming majority of LS patients have never been told it exists.

This article covers what it is, what the research actually shows, and who is most likely to benefit from it.

What PDRN Actually Is

PDRN stands for polydeoxyribonucleotide. It is a biologically active compound made from purified DNA fragments extracted from the sperm cells of salmon trout. The molecular weight of these fragments ranges from 50 to 1,500 kilodaltons, and this specific molecular weight range determines PDRN's biological activity and distinguishes it from other DNA-derived compounds with different fragment profiles.

Because PDRN consists of purified DNA fragments without proteins or peptides, it carries very low immunogenicity. It does not trigger immune rejection or allergic responses, which gives it an excellent safety profile across a wide range of tissues including genital mucosa. For LS patients whose tissue is already sensitized and reactive, this tolerability profile matters considerably.

The commercial injectable product used in clinical studies is Placentex injectable solution, manufactured by Mastelli S.r.l. in Sanremo, Italy. It is a registered pharmaceutical drug available in injectable vials of 5.625mg per 3ml, formulated for intradermal and subdermal use. The injectable form requires medical administration by a clinician. Mastelli also produces a topical gel product under the name Turnover, but this is a separate product entirely and is not what the clinical LS studies used. Throughout this article, when we say Placentex, we mean specifically the injectable solution and not any topical cream or gel product. The distinction matters because the evidence base belongs to the injectable form alone.

How PDRN Works in Tissue and Why It Makes Sense for LS

The adenosine A2A receptor mechanism

When PDRN is administered by injection, nuclease enzymes in the plasma and tissue break down its DNA chains and release adenosine. That adenosine binds to adenosine A2A receptors on local cells, triggering a cascade of biological effects that are directly relevant to the specific problems LS tissue develops over time. The most important downstream effects are upregulation of VEGF, which drives new blood vessel formation, stimulation of fibroblast proliferation and activity, and reduction of pro-inflammatory cytokines including TNF-α and IL-1β.

We know A2A receptor binding is the actual mechanism because a selective A2A antagonist called DMPX abolishes PDRN's effects completely when introduced in experimental conditions. This pharmacological specificity gives the mechanism considerably more credibility than treatments where the biological pathway is inferred rather than demonstrated.

Why does this matter for LS specifically? Atrophic LS tissue is often poorly vascularized. The white, thin, depleted appearance of established LS reflects structural changes that go beyond inflammation alone. Poor blood supply means poor oxygenation, poor nutrient delivery, and poor capacity for tissue repair. Even when the immune component is well controlled by steroids, the tissue cannot easily rebuild itself if the vascular architecture supporting that rebuilding has been compromised. PDRN's A2A-mediated VEGF upregulation addresses this at the vascular level through a mechanism that no existing first-line LS treatment shares.

The salvage pathway mechanism

A secondary mechanism is direct nucleotide provision. PDRN fragments enter the cell's DNA salvage pathway, providing ready-made building blocks for DNA synthesis and cellular repair without the energy cost of constructing them from scratch. In tissue under chronic stress, as LS epithelium certainly is, this metabolic support may facilitate more efficient cellular repair and turnover at a baseline level. The salvage pathway contribution is considered secondary to the A2A mechanism in terms of magnitude of effect, but it is not trivial. Chronically inflamed tissue has elevated metabolic demands and reduced biosynthetic capacity, and providing substrate directly rather than requiring de novo synthesis has logical appeal.

The biological profile that fits PDRN to LS

Understanding where PDRN sits within the broader treatment landscape requires being honest about what it does well and what it does less well. PDRN is a repair-biased molecule. Its strongest argument is for tissue that is regeneration-poor, thin, atrophic, and slow to heal, rather than for tissue dominated by an active cytokine-driven flare. This places it most naturally in Phase 2, the closing and fragile transition phase, and Phase 3, the fibrotic and atrophic phase where structural depletion has become the dominant clinical problem.

In Phase 1, active immune inflammation is the primary driver, and steroid management is what the tissue needs most. PDRN's anti-inflammatory contribution through A2A signaling is real but insufficient as a standalone response to acute NF-κB-driven cytokine cascades. In Phase 2, where barriers are closing and regeneration is poor, the case for injectable PDRN becomes compelling because tissue is past the acute inflammatory peak but has not recovered its structural integrity. In Phase 3, where fibrosis and atrophy have reshaped the tissue architecture, PDRN is most relevant for the atrophic end of the spectrum where thinning and poor vascularization dominate, and less central for dense established fibrosis where antifibrotic approaches carry more direct relevance.

For more on how these phases work and how to identify which one you are in, see Steroids and Treatment Logic in Lichen Sclerosus: A Complete Guide and Is Lichen Sclerosus Progressive? What Progression Really Means.

What the Research in Lichen Sclerosus Actually Shows

The evidence base is not large. That matters and will be addressed clearly in the limitations section. But what exists is consistent in direction, mechanistically coherent, and comes from independent research groups working in urology and dermatology settings in Italy, where injectable Placentex has been available and studied for longer than in most other countries. Consistency across independent groups, even in small studies, carries more interpretive weight than a single large positive result.

Laino 2012: the first clinical observation

The first published report of PDRN in LS appeared in the European Journal of Dermatology in 2012. Laino documented adjuvant clinical effects when injectable PDRN was combined with standard corticosteroid treatment, including improvements in inflammation, atrophy, leukoplakia, and pigmentation, with long-standing remissions observed after eight injection sessions. This was a brief initial observation rather than a controlled study, but it established the proof of concept that PDRN injection adds benefit beyond what steroids achieve alone and identified which clinical signs responded.

Laino 2013: controlled comparison in male genital LS

The most methodologically detailed study was published in Dermatology Research and Practice in 2013, with full text available at PMC3893745. Twenty-eight male patients aged 25 to 65 with genital lichen sclerosus were divided into two groups. Group A received intradermal Placentex injectable solution at 5.625mg per 3ml combined with clobetasol propionate 0.05% cream. Group B received clobetasol alone. Both groups were assessed using the Investigator's Global Assessment and the Dermatology Life Quality Index.

Group A showed regression of most clinical and pathological signs. Photographic documentation showed, in some cases, complete resolution of ecchymotic areas of the glans, complete resolution of lichenoid inflammatory areas and preputial fissures, and significant improvement in sclerotic preputial rings with partial repigmentation. Group B showed only moderate improvement. No adverse events were recorded in either group. The conclusion was direct: intradermal Placentex injectable combined with clobetasol was associated with clearly better clinical improvement than clobetasol in single therapy.

Zucchi et al. 2016: 21 patients including diabetics and hypertensives

Zucchi, Cai, Cavallini, and colleagues published a prospective pilot study in Urologia Internationalis evaluating PDRN locoregional injection therapy in 21 male patients with genital LS. This study is particularly significant because it included diabetic and hypertensive patients, populations for whom intensive steroid use creates real metabolic concerns and where a regenerative approach that does not carry systemic hormonal effects has clear clinical value.

All patients received weekly injectable PDRN sessions for two cycles of ten sessions. DLQI scores dropped from an average of 15 to 4, which is a statistically highly significant improvement with a p-value below 0.0001. Eighty percent of patients considered their post-treatment condition improved on the Patient Global Impression of Improvement questionnaire. Tissue trophism, skin elasticity, and irritative symptoms all improved. Tolerability was excellent throughout the treatment course. Sexual function scores did not show statistically significant change, which the authors attributed to the structural nature of some sexual dysfunction in established LS rather than to any limitation of PDRN itself.

Arena and Romeo 2016: the pediatric LS dimension

The commentary from Arena and Romeo at the University of Messina's Paediatric Surgery unit adds a clinical dimension that is easy to overlook. At their unit, approximately 45% of pediatric patients undergoing circumcision for secondary phimosis were found to have LS, confirming the underrecognized prevalence of pediatric LS in phimosis cases. The authors note that steroids carry side effects and are sometimes contraindicated even in children, particularly with diabetes, and propose injectable PDRN as a potentially important alternative approach. They also raise the question of whether a topical PDRN formulation could be explored for pediatric patients where needle administration is impractical, though they are explicit that the clinical evidence exists for the injectable form only and that multicentric randomized trials are needed.

What systematic reviews conclude

Multiple systematic reviews and pharmacological overviews have now incorporated the PDRN LS data into their syntheses. The Frontiers in Pharmacology review by Squadrito and colleagues states that Placentex injectable subdermal injections combined with daily topical corticosteroids resulted in marked reduction of most clinical signs. The 2024 systematic review of treatment modalities for genital LS explicitly identifies PDRN injection as one of the adjunct therapies that has proven to improve patient outcomes and can be used in conjunction with high-potency topical corticosteroids. The narrative dermatology review in the Journal of Cutaneous and Aesthetic Surgery notes long-standing remissions in LS after intradermal PDRN injection combined with topical steroids.

The direction of findings across independent sources is consistent. This is not a single group's positive result being cited forward uncritically. Multiple reviewers synthesizing the evidence from different angles reach the same conclusion: injectable PDRN adds meaningful benefit as an adjunct to standard steroid management in LS.

PDRN versus Steroids: Understanding What Each One Does

What steroids do and what they leave undone

Topical corticosteroids, whether clobetasol, mometasone, or hydrocortisone, suppress the Th1 immune activation that drives LS. They reduce IFN-γ, TNF-α, and IL-1β signaling, interrupt NF-κB amplification, and calm mast cell activity at the tissue level. This is why they work and why they remain irreplaceable for active immune flares. Understanding their mechanism makes clear why they are necessary.

What steroids do not do is rebuild atrophic tissue. They do not improve vascular supply to depleted epithelium. They do not drive fibroblast regenerative activity or support epithelial turnover in chronically thinned tissue. Long-term high-potency steroid use can even contribute to tissue thinning in some contexts through mechanisms distinct from the disease itself, which is one of the legitimate concerns that informs thinking about maintenance protocols and steroid-sparing strategies. Immune control and tissue regeneration are different biological problems, and treating one does not automatically resolve the other.

For more on how steroids work in LS and when each potency is appropriate, see How to Use Clobetasol Correctly for Lichen Sclerosus and Steroid Maintenance vs Overuse in Lichen Sclerosus.

What injectable PDRN adds that steroids cannot

PDRN injection addresses the regenerative deficit that steroids leave untreated. When LS tissue has been chronically inflamed and structurally depleted, controlling the immune component does not automatically restore what has been lost at the tissue architecture level. The basement membrane damage, the vascular depletion, the thinning of the epithelial layers, and the ceramide-poor barrier dysfunction that characterize established LS all represent structural problems that require regenerative input, not just immune suppression.

PDRN's A2A-mediated VEGF upregulation, fibroblast stimulation, and nucleotide provision address this regenerative gap directly. The clinical data consistently shows injectable PDRN working best as an adjuvant to steroids rather than as a replacement for them, and the biological logic fully supports this positioning. Immune control and tissue regeneration are complementary targets. They are not competing approaches. They address different aspects of the same damaged tissue, and the evidence suggests treating both simultaneously produces meaningfully better outcomes than treating only one.

The patient profile that benefits most from injectable PDRN

The patients for whom injectable PDRN has the strongest biological argument share a recognizable clinical picture. Inflammation is adequately controlled by the existing steroid protocol, but tissue quality remains poor: thin, fragile, and persistently symptomatic at a level below active flare. Fissures recur in the same locations and close slowly or incompletely despite good inflammation management, which suggests the regenerative capacity of the tissue rather than the immune component is the limiting factor. The plaques feel cold or stiff, white from structural depletion rather than active inflammation, with signs of poor local vascularization that point toward a VEGF-responsive problem.

Patients with diabetes or other conditions where intensive steroid use is metabolically problematic represent a particular subgroup where injectable PDRN's steroid-sparing regenerative contribution has real clinical value, as the Zucchi 2016 study directly demonstrated. Patients who have optimized their primary management and plateaued are also strong candidates: when the remaining symptom burden relates to tissue quality rather than immune activity, the tools that target immune activity will not move the dial further. For more on why some patients plateau despite correct steroid use, see Why Lichen Sclerosus Flares Come Back Even When You Are Doing Everything Right.

The Injectable Placentex Protocol: What Clinical Studies Used

Concentration and administration

The form used in all published LS clinical studies is Placentex injectable solution, specifically 5.625mg PDRN in a 3ml vial, administered intradermally or subdermally into the affected tissue by a clinician. This is not a cream, not a topical product, and not something a patient applies at home. It is a medical procedure requiring injection into genital tissue by someone with appropriate training and experience in that tissue context.

Different published protocols vary somewhat in their approach. The Zucchi 2016 study used weekly injection sessions in two cycles of ten sessions each. The Laino 2012 and 2013 work used eight injection sessions combined with daily topical steroid. No single protocol has been established as definitively optimal because the comparative data to distinguish between approaches does not yet exist. Clinicians implementing this treatment draw on the published protocols while adapting to patient-specific factors including disease severity, phase, and the condition of the tissue at each session.

The topical formulation: what it is and what it is not

Mastelli also produces Turnover, a topical gel with a lower PDRN concentration. This is a separate product from the injectable Placentex solution and has not been studied in LS clinical trials. There is no published evidence for topical PDRN in LS specifically, and patients should understand this distinction clearly rather than assuming that any PDRN-containing product carries the evidence base that belongs to the injectable form.

The honest position on topical PDRN is this: on barrier-compromised LS tissue, penetration of topical actives is higher than on normal skin because the protective stratum corneum is structurally impaired by ceramide depletion and chronic damage. This makes topical application biologically more plausible for LS patients than for patients with intact skin, and the tolerability profile across all PDRN research is excellent. But biological plausibility is not clinical evidence. Patients interested in this area should understand that the topical form represents a low-risk exploratory option, not a substitute for the injectable protocol that the clinical studies support.

PDRN in Context with Other Regenerative Approaches

PDRN versus PRP

Platelet-rich plasma is the other regenerative injectable approach most discussed in LS. Both PRP and PDRN target the regenerative deficit rather than the immune component, which places them in the same therapeutic space conceptually. Their evidence profiles differ meaningfully, however. A randomized double-blind placebo-controlled trial of PRP in vulvar LS found no statistically significant improvement over saline placebo, which is a sobering result from a well-designed study. Other PRP studies have shown improvements but with less rigorous methodology, making interpretation difficult.

PDRN injection has a more consistent mechanistic basis through A2A receptor biology and a more consistent direction of findings across independent groups. The evidence base for PDRN is smaller in total patient numbers but more directionally uniform across the studies that exist. Neither approach has large randomized controlled trial data. The preliminary signal for injectable PDRN is stronger, and the mechanism is better characterized.

PDRN versus CO2 fractional laser

Fractional CO2 laser creates controlled micro-injury to stimulate collagen remodeling and tissue regeneration through a fundamentally different pathway than PDRN. It is most relevant for established fibrotic Phase 3 tissue with loss of elasticity and architectural change. Injectable PDRN targets the regenerative deficit somewhat earlier, in Phase 2 closing tissue and early Phase 3, through vascular and cellular biology rather than thermal remodeling. These are not competing approaches for the same patients. In appropriate clinical settings, a clinician might consider them as sequential interventions: injectable PDRN during the regenerative phase where tissue is closing and vascular support is the priority, and laser for established fibrosis once inflammation is fully controlled. Laser cannot be used during active inflammatory phases, while injectable PDRN can be used during Phase 2 tissue states where laser would be contraindicated, which gives them different and partially complementary clinical windows.

Where injectable PDRN fits in the phase framework

During Phase 1, active immune flare, PDRN injection is not the primary tool. Steroid management is. PDRN's anti-inflammatory contribution through A2A signaling is insufficient to manage the NF-κB-driven cytokine cascade that defines an acute flare, and introducing a regenerative stimulus into actively inflamed tissue is not the biological priority at that moment.

During Phase 2, the closing and fragile transition state, injectable PDRN has its strongest biological argument. Tissue is past the acute inflammatory peak but remains regeneration-poor, with barrier integrity still compromised and healing capacity limited. A2A-driven VEGF upregulation and fibroblast stimulation directly support re-epithelialization and vascular repair alongside continuing steroid management. This is the phase where the combination approach the clinical studies used is most directly applicable.

During Phase 3, the fibrotic and atrophic phase, injectable PDRN is relevant for the atrophic end of the spectrum where tissue is thin and depleted. For dense established fibrosis where the dominant problem is excess collagen deposition rather than tissue thinning, antifibrotic approaches carry more direct relevance, though atrophy and fibrosis frequently coexist in the same tissue.

During Phase 4, remission and fragile stability, repeat injectable PDRN cycles may be worth considering for patients with persistently fragile baseline tissue quality even during controlled periods. The two-day delay mechanism, whereby mechanical micro-injury produces immune activation 12 to 48 hours after the event, means that fragile tissue in remission can still cycle back toward inflammation through ordinary physical contact. Maintaining tissue structural integrity in Phase 4 is itself a form of relapse prevention, and this is where PDRN's regenerative contribution to maintenance logic has a coherent place.

Practical Information for Patients Considering Injectable PDRN

Finding appropriate care

Intradermal PDRN injection for LS is not yet standard of care outside specialist dermatology and urology. In Italy, it is most available through dermatology and urology units with LS experience, reflecting the longer history of Placentex use in that clinical culture. Outside Italy, access is more variable and patients may need to seek out clinicians who have incorporated regenerative injectable approaches into their LS practice specifically. When seeking this approach, it matters to ask about the clinician's experience with injectable PDRN for LS as opposed to aesthetic rejuvenation applications, because the protocols, injection depth, tissue context, and clinical goals are different enough that aesthetic experience does not straightforwardly transfer to LS management.

What to expect realistically

The clinical data shows consistent improvement in tissue quality, symptom burden, and quality of life scores. In the Zucchi 2016 study, DLQI scores dropped from 15 to 4, which represents a major improvement in daily quality of life impact across 21 patients, with 80% reporting their condition improved on a validated patient-reported measure. These are meaningful clinical outcomes. They are not cure. They are significant, sustained improvement in a condition that is otherwise difficult to move beyond a plateau once primary management has been optimized.

Response is not immediate. Regenerative tissue repair is a biological process that takes weeks to become visible as the vascular and cellular changes work through the tissue architecture. Published protocols involve multiple injection sessions over weeks to months, not single treatments, and patients should approach this with realistic expectations about the timeline of response. The improvements documented in published studies emerged over the full treatment course, not after a single session.

How injectable PDRN fits alongside existing management

Injectable PDRN does not replace any component of standard LS management. The steroid protocol remains the primary immune control strategy and should not be discontinued or reduced because a regenerative approach is being added. Barrier protection remains essential because the two-day delay mechanism and trigger amplification loops that drive LS flares remain operative regardless of regenerative treatment. PDRN injection is an add-on regenerative layer for patients who have optimized their primary management and have a specific tissue regeneration problem that existing tools do not address.

For more on building a complete management approach, see Daily Care for Lichen Sclerosus: The Complete System for Stability and Natural Treatments for Lichen Sclerosus: What Actually Helps and What Often Makes It Worse.

What the Evidence Does Not Yet Tell Us

The published injectable PDRN LS studies are small. The largest enrolled 28 patients. None are randomized, double-blind, and placebo-controlled. All published studies come from Italian research groups, meaning independent international replication is absent. The Arena and Romeo commentary explicitly calls for multicentric randomized clinical trials, and those trials have not yet been conducted. For a condition affecting millions of people globally, the absence of large-scale trial data reflects a broader problem with LS research funding and clinical prioritization rather than anything specific to PDRN.

The optimal injection protocol has not been established by comparative data. Different published protocols vary in session frequency, total treatment duration, and tissue targeting in ways that may matter for outcome but cannot currently be ranked against each other. Long-term follow-up data beyond six months is limited, meaning whether repeat injectable PDRN cycles are needed to maintain improvements and at what intervals remains unknown.

Female genital LS has less published data than male genital LS in the PDRN injection literature. The mechanism operates at the tissue level and is not sex-specific, and there is no biological reason to expect fundamentally different results in female genital tissue, but the published clinical evidence is thinner on this side and patients and clinicians should acknowledge that gap honestly.

These limitations do not make the existing evidence meaningless. They define what injectable PDRN currently is: a genuinely promising approach supported by mechanistically coherent evidence and a consistent direction of preliminary clinical findings, but not yet a fully characterized treatment with established protocols and long-term data from thousands of patients. The appropriate response to this evidence profile is informed discussion with a specialist, not either dismissal or uncritical enthusiasm.

Why This Matters for Patients Right Now

The gap that injectable PDRN addresses is real and currently underserved in LS management. Steroids manage the immune component of LS effectively when used correctly. Nothing in current standard management addresses the regenerative deficit that accumulates in tissue that has been chronically inflamed, structurally depleted, and slow to recover. The barrier disruption, vascular depletion, and impaired epithelial turnover that characterize established atrophic LS are not problems that immune suppression alone can reverse, and the absence of a regenerative tool in standard care represents a genuine gap in what patients are being offered.

For patients who are doing everything right on the management side but whose tissue remains fragile, thin, and persistently problematic, there is a biologically coherent, clinically supported, safe option that most of them have never been offered and that most clinicians outside specialist settings have not yet incorporated into their thinking. The mechanisms are characterized at the pharmacological level. The clinical findings across independent groups point in the same direction. The safety profile across all published research is excellent.

That is the honest case for knowing about injectable PDRN. Not that it cures LS. Not that it replaces steroids or any other component of sound management. But that it addresses a biological problem that nothing else currently addresses, in a way that the preliminary evidence consistently supports, and that patients with the right clinical profile deserve to know about as an option to discuss with a specialist who understands both the potential and the current limits of the evidence.

For more on what other advanced options exist and how they fit into LS management, see Does Lichen Sclerosus Always Scar? What's Permanent vs What Isn't and Lichen Sclerosus and Cancer Risk: What Actually Matters.

‍

Content sourced from: Lichen Sclerosus Decoded, A New Way to Understand and Manage Lichen Sclerosus. For informational purposes only. This article does not constitute medical advice. Please consult a qualified healthcare provider for diagnosis and treatment.

‍

Scientific References

Book by Alex Force

Lichen Sclerosus Decoded: A New Way to Understand and Manage Lichen Sclerosus

The phase-based framework that explains why symptoms change, why treatments sometimes stop working, and what you can actually do about it. Written for patients who want to understand the biology, not just follow instructions.

Read on Amazon →

Credits

No items found.